Development of a Risk Stratification Score for Recurrent Venous Thromboembolism and Treatment-related Clinically Relevant Bleeding in Patients With Cancer-associated Thrombosis

Recruiting now

Conditions studied: Cancer-associated Thrombosis

In brief

The objective of this study is to prospectively develop a risk assessment model (RAM) that accurately identifies anticoagulated cancer-associated thrombosis (CAT) patients at low- and high-risk of recurrent venous thromboembolism (VTE) and clinically relevant bleeding within 6 months following the CAT diagnosis and to create a biobank of plasma and whole blood samples for further translational research in cancer genetics and hemostasis.

Key facts

Study ID

NCT06894576

Run by

Ottawa Hospital Research Institute

People needed

1000

Starts

2024-12-03

Expected to finish

2027-12-01

Last updated by the study team

2025-03-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Objectively documented distal and/or proximal DVT of the limb (upper or lower extremity) and/or PE, splanchnic vein thrombosis and/or cerebral sinus vein thrombosis in presence of active cancer of all types
• Intended treatment of CAT for at least 6 months with parenteral or oral anticoagulants at therapeutic dosing.
• Estimated life expectancy > 6 months
• Willingness to give an informed consent
• Age ≥ 18 years

You may not qualify if…

• Unusual site CAT (gonadal vein thrombosis, ovarian vein thrombosis, retinal vein thrombosis)
• Superficial vein thrombosis
• Refusal of informed consent > 72 hrs of anticoagulants
• Age < 18 years old

Where it is running

• Ottawa Hospital Research Institute — Ottawa, Ontario, Canada (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.